The system produces purified cell populations for downstream processing research and commercial manufacture, improving overall process performance
Invetech’s new Korus Counterflow Centrifugation system is designed for Elutriation and Cell Wash. (Credit: PR Newswire/ Invetech)
Diagnostic device maker Invetech has launched Korus, a closed system for autologous cell therapies that features elutriation and cell wash using gentle counterflow centrifugation.
According to the firm, Korus can transform cell therapy industry standards by improving manufacturing performance compared to samples prepared by standard washing.
The system produces purified cell populations for downstream processing research and commercial manufacture, improving overall process performance through higher recovery and purity of target cells.
With Invetech’s innovative Korus system, developers can now expedite clinical development and scale out their products effectively.
The system uses a gentle elutriation process to provide a cleaner cell population for cell therapy production.
Invetech president Andreas Knaack said: “To fast-track the commercialisation of cell and gene therapies, our industry needs efficient and scalable manufacturing technologies that can deliver high-quality therapies cost-effectively.
“Invetech’s new technology offering, as demonstrated by our new Korus system, represents our continued commitment to helping make life-saving therapies accessible to more patients.”
The company said that better downstream performance, including higher target cell recovery during selection and higher cell growth during expansion, is witnessed when Korus technology is incorporated into a cell therapy manufacturing process.
Invetech Cell Therapy Science & Application team leader Jon Ellis said: “Manufacturing efficiency of cell therapies needs improvement and innovation if the cell therapy industry is going to reach its commercialisation goals.
“Our data shows that whilst achieving similar apheresis lymphocyte cell recovery to the control wash process, Korus eluted lymphocytes to high purity which resulted in improvements in downstream performance including greater Dynabead cell selection recovery and fold expansion.”
Ellis added: “Overall, this innovation in cell processing will reduce the impact of starting material variability, contribute to higher manufacturing yield and reduced risk of batch failure; and potentially reduce the cost of goods for future therapies.”
Invetech said that the Korus system is intended for research, laboratory or further manufacturing use only.
The system is not intended as a medical device for therapeutic or diagnostic procedures.